Three studies report promising results in the use of cutting-edge genome editing and cellular therapies for hard-to-treat blood disorders and cancers.

52 physicians from across the U.S. selected for the inaugural cohort of the five-year, $100 million initiative Initiative is part of the BMS Foundation commitment...

ZEPOSIA, a treatment for multiple sclerosis is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation

The global telemedicine market size is expected to reach USD 298.9 billion by 2028, according to a new report by Grand View Research